WHITEHALL-ROBINS' Rx-TO-OTC SWITCH APPLICATION FOR ORUDIS FILED
This article was originally published in The Tan Sheet
WHITEHALL-ROBINS' Rx-TO-OTC SWITCH APPLICATION FOR ORUDIS FILED in late 1993 with FDA, the company said in its recently released annual report for the year. Whitehall-Robins' parent company American Home Products described the Rx-to-OTC switches of the nonsteroidal anti-inflammatory Orudis and the H antagonist Axid as "high priority" projects last fall when the company announced it was canceling an agreement to market ChemTrak's OTC cholesterol test to focus on the two switches ("The Tan Sheet" Oct. 18, 1993, p. 6). Marketed in the U.S. as a prescription drug by AHP's Wyeth-Ayerst subsidiary since 1986, Orudis (ketoprofen) was licensed from Rhone-Poulenc Rorer.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC